Invivyd (IVVD) Asset Utilization Ratio (2024 - 2025)
Invivyd (IVVD) posted Asset Utilization Ratio of 0.26 for Q4 2025, down 41.41% on a QoQ basis from 0.44 in Q3 2025, and up 47.44% year-over-year from 0.17 in Q4 2024.
Invivyd (IVVD) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
Invivyd's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.26 for Q4 2025.
- Quarterly Asset Utilization Ratio rose 47.44% year-over-year to 0.26 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.26 (up 47.44% YoY) and the FY2025 annual result came in at 0.26, up 85.77% from the prior year.
- Asset Utilization Ratio was 0.26 for Q4 2025 at Invivyd, down from 0.44 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.48 in Q2 2025 and bottomed at 0.01 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.69 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.44 |
| Jun 30, 2025 | 0.48 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | 0.17 |
| Sep 30, 2024 | 0.07 |
| Jun 30, 2024 | 0.01 |